FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis

Clinical trial NCT06801665 · RECRUITING

Trial details

NCT number: NCT06801665
Sponsor: Hua Jiang
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Colon Cancer Liver Metastases

Start date: 2025-04-17
Primary completion: 2027-02-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.